{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:03:44Z","timestamp":1790193824155,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>Breast cancer tumour-infiltrating lymphocytes associate with clinico-pathological factors, including survival, although the literature includes many conflicting findings. Our aim was to assess these associations for key lymphocyte subtypes and in different tumour compartments, to determine whether these provide differential correlations and could, therefore, explain published inconsistencies. Uniquely, we also examine whether infiltrating levels merely reflect systemic lymphocyte levels or whether local factors are predominant in recruitment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Immunohistochemistry was used to detect tumour-infiltrating CD20+ (B), CD4+ (helper T), CD8+ (cytotoxic T) and FoxP3+ (regulatory T) cells in breast cancers from 62 patients, with quantification in tumour stroma, tumour cell nests, and tumour margins. Levels were analysed with respect to clinico-pathological characteristics and matched circulating levels (determined by flow-cytometry).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>CD4+ lymphocytes were the most prevalent subtype in tumour stroma and at tumour edge and CD8+ lymphocytes were most prevalent in tumour nests; FoxP3+ lymphocytes were rarest in all compartments. High grade or hormone receptor negative tumours generally had significantly increased lymphocytes, especially in tumour stroma. Only intra-tumoural levels of CD8+ lymphocytes correlated significantly with matched circulating levels (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.03), suggesting that recruitment is mainly unrelated to systemic activity. High levels of stromal CD4+ and CD20+ cells associated with improved survival in hormone receptor negative cases (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.04), while tumour nest CD8+ and FoxP3+ cells associated with poor survival in hormone receptor positives (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.005).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Lymphocyte subtype and location define differential impacts on tumour biology, therefore, roles of tumour-infiltrating lymphocytes will only be unravelled through thorough analyses that take this into account.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s10549-020-05757-5","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T06:03:36Z","timestamp":1592892216000},"page":"49-59","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer"],"prefix":"10.1007","volume":"183","author":[{"given":"Rashmi","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Hanby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Horgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldo T.","family":"Verghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milene","family":"Volpato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive R.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1169-3386","authenticated-orcid":false,"given":"Thomas A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"key":"5757_CR1","doi-asserted-by":"publisher","first-page":"103753","DOI":"10.1016\/j.cellimm.2018.01.013","volume":"343","author":"G Badalamenti","year":"2019","unstructured":"Badalamenti G, Fanale D, Incorvaia L, Barraco N, Listi A, Maragliano R, Vincenzi B, Calo V, Iovanna JL, Bazan V, Russo A (2019) Role of tumor-infiltrating lymphocytes in patients with solid tumors: can a drop dig a stone? Cell Immunol 343:103753. https:\/\/doi.org\/10.1016\/j.cellimm.2018.01.013","journal-title":"Cell Immunol"},{"issue":"4","key":"5757_CR2","doi-asserted-by":"publisher","first-page":"101042831769502","DOI":"10.1177\/1010428317695023","volume":"39","author":"A Ravelli","year":"2017","unstructured":"Ravelli A, Roviello G, Cretella D, Cavazzoni A, Biondi A, Cappelletti MR, Zanotti L, Ferrero G, Ungari M, Zanconati F, Bottini A, Alfieri R, Petronini PG, Generali D (2017) Tumor-infiltrating lymphocytes and breast cancer: beyond the prognostic and predictive utility. Tumour Biol 39(4):1010428317695023. https:\/\/doi.org\/10.1177\/1010428317695023","journal-title":"Tumour Biol"},{"issue":"3","key":"5757_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/COC.0b013e3182467d90","volume":"36","author":"ST Kim","year":"2013","unstructured":"Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH (2013) Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol 36(3):224\u2013231. https:\/\/doi.org\/10.1097\/COC.0b013e3182467d90","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"5757_CR4","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.3892\/ol.2018.9853","volume":"17","author":"Y Miyoshi","year":"2019","unstructured":"Miyoshi Y, Shien T, Ogiya A, Ishida N, Yamazaki K, Horii R, Horimoto Y, Masuda N, Yasojima H, Inao T, Osako T, Takahashi M, Tomioka N, Wanifuchi-Endo Y, Hosoda M, Doihara H, Yamashita H (2019) Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive\/human epidermal growth factor receptor type 2 negative breast cancer. Oncol Lett 17(2):2177\u20132186. https:\/\/doi.org\/10.3892\/ol.2018.9853","journal-title":"Oncol Lett"},{"issue":"7","key":"5757_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S (2019) Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol 37(7):559\u2013569. https:\/\/doi.org\/10.1200\/JCO.18.01010","journal-title":"J Clin Oncol"},{"issue":"4","key":"5757_CR6","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1245\/s10434-017-6332-2","volume":"25","author":"N Jang","year":"2018","unstructured":"Jang N, Kwon HJ, Park MH, Kang SH, Bae YK (2018) Prognostic value of tumor-infiltrating lymphocyte density assessed using a standardized method based on molecular subtypes and adjuvant chemotherapy in invasive breast cancer. Ann Surg Oncol 25(4):937\u2013946. https:\/\/doi.org\/10.1245\/s10434-017-6332-2","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"5757_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s12282-017-0822-8","volume":"25","author":"H Inoue","year":"2018","unstructured":"Inoue H, Horii R, Ito Y, Iwase T, Ohno S, Akiyama F (2018) Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer. Breast Cancer 25(3):268\u2013274. https:\/\/doi.org\/10.1007\/s12282-017-0822-8","journal-title":"Breast Cancer"},{"issue":"2","key":"5757_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S, International TWG","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S, International TWG (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259\u2013271. https:\/\/doi.org\/10.1093\/annonc\/mdu450","journal-title":"Ann Oncol"},{"key":"5757_CR9","doi-asserted-by":"publisher","DOI":"10.1159\/000504055","author":"NM Badr","year":"2019","unstructured":"Badr NM, Berditchevski F, Shaaban AM (2019) The immune microenvironment in breast carcinoma: predictive and prognostic role in the neoadjuvant setting. Pathobiology. https:\/\/doi.org\/10.1159\/000504055","journal-title":"Pathobiology"},{"issue":"8","key":"5757_CR10","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","volume":"25","author":"HR Ali","year":"2014","unstructured":"Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, Earl HM, Poole CJ, Hiller L, Dunn JA, Bowden SJ, Twelves C, Bartlett JM, Mahmoud SM, Rakha E, Ellis IO, Liu S, Gao D, Nielsen TO, Pharoah PD, Caldas C (2014) Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol 25(8):1536\u20131543. https:\/\/doi.org\/10.1093\/annonc\/mdu191","journal-title":"Ann Oncol"},{"issue":"2","key":"5757_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10549-011-1620-1","volume":"132","author":"SM Mahmoud","year":"2012","unstructured":"Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR (2012) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 132(2):545\u2013553. https:\/\/doi.org\/10.1007\/s10549-011-1620-1","journal-title":"Breast Cancer Res Treat"},{"key":"5757_CR12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1402","author":"C De Angelis","year":"2019","unstructured":"De Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, Zheng Y, Veeraraghavan J, Sethunath V, Nuciforo P, Wang T, Tsimelzon A, Mao S, Hilsenbeck SG, Trivedi MV, Cataldo ML, Pavlick A, Wolff AC, Weigelt B, Reis-Filho JS, Prat A, Gutierrez C, Osborne CK, Rimawi MF, Schiff R (2019) Evaluation of the predictive role of tumor immune infiltrate in patients with HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy without chemotherapy. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1402","journal-title":"Clin Cancer Res"},{"key":"5757_CR13","doi-asserted-by":"publisher","first-page":"36231","DOI":"10.1038\/srep36231","volume":"6","author":"AM Khan","year":"2016","unstructured":"Khan AM, Yuan Y (2016) Biopsy variability of lymphocytic infiltration in breast cancer subtypes and the ImmunoSkew score. Sci Rep 6:36231. https:\/\/doi.org\/10.1038\/srep36231","journal-title":"Sci Rep"},{"issue":"1","key":"5757_CR14","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41598-018-38272-1","volume":"9","author":"S Kurozumi","year":"2019","unstructured":"Kurozumi S, Inoue K, Matsumoto H, Fujii T, Horiguchi J, Oyama T, Kurosumi M, Shirabe K (2019) Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer. Sci Rep 9(1):1583. https:\/\/doi.org\/10.1038\/s41598-018-38272-1","journal-title":"Sci Rep"},{"issue":"10","key":"5757_CR15","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00262-019-02327-7","volume":"68","author":"CN Baxevanis","year":"2019","unstructured":"Baxevanis CN, Sofopoulos M, Fortis SP, Perez SA (2019) The role of immune infiltrates as prognostic biomarkers in patients with breast cancer. Cancer Immunol Immunol 68(10):1671\u20131680. https:\/\/doi.org\/10.1007\/s00262-019-02327-7","journal-title":"Cancer Immunol Immunol"},{"key":"5757_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.bbcan.2017.10.003","volume":"1868","author":"GD de Melo","year":"2017","unstructured":"de Melo GD, Cortes J, Curigliano G, Loi S, Denkert C, Perez-Garcia J (2017) Tumor-infiltrating lymphocytes in breast cancer and implications for clinical practice. BBA-Rev Cancer 1868:527\u2013537. https:\/\/doi.org\/10.1016\/j.bbcan.2017.10.003","journal-title":"BBA-Rev Cancer"},{"issue":"1","key":"5757_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13058-015-0669-x","volume":"18","author":"R Verma","year":"2016","unstructured":"Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, Hughes TA, Carter CR (2016) Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res 18(1):10. https:\/\/doi.org\/10.1186\/s13058-015-0669-x","journal-title":"Breast Cancer Res"},{"issue":"2","key":"5757_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10549-006-9242-8","volume":"100","author":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of NCIEWGoCD","year":"2006","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of NCIEWGoCD (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229\u2013235. https:\/\/doi.org\/10.1007\/s10549-006-9242-8","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"5757_CR19","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/j.1365-2559.2011.03846.x","volume":"58","author":"K Baker","year":"2011","unstructured":"Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD (2011) Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 58(7):1107\u20131116. https:\/\/doi.org\/10.1111\/j.1365-2559.2011.03846.x","journal-title":"Histopathology"},{"key":"5757_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/Bcr3148","author":"SZ Liu","year":"2012","unstructured":"Liu SZ, Lachapelle J, Leung S, Gao DX, Foulkes WD, Nielsen TO (2012) CD8(+) lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. https:\/\/doi.org\/10.1186\/Bcr3148","journal-title":"Breast Cancer Res"},{"issue":"8","key":"5757_CR21","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/annonc\/mdv239","volume":"26","author":"MV Dieci","year":"2015","unstructured":"Dieci MV, Mathieu MC, Guarneri V, Conte P, Delaloge S, Andre F, Goubar A (2015) Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol 26(8):1698\u20131704. https:\/\/doi.org\/10.1093\/annonc\/mdv239","journal-title":"Ann Oncol"},{"issue":"5","key":"5757_CR22","first-page":"543","volume":"100","author":"MM Black","year":"1955","unstructured":"Black MM, Opler SR, Speer FD (1955) Survival in breast cancer cases in relation to the structure of the primary tumor and regional lymph nodes. Surg Gynecol Obstet 100(5):543\u2013551","journal-title":"Surg Gynecol Obstet"},{"key":"5757_CR23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/0959-8049(92)90134-N","volume":"28","author":"S Aaltomaa","year":"1992","unstructured":"Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjanen K (1992) Lymphocyte infiltrates as a prognostic variable in female breast-cancer. Eur J Cancer 28:859\u2013864. https:\/\/doi.org\/10.1016\/0959-8049(92)90134-N","journal-title":"Eur J Cancer"},{"issue":"6","key":"5757_CR24","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/his.13695","volume":"73","author":"M Althobiti","year":"2018","unstructured":"Althobiti M, Aleskandarany MA, Joseph C, Toss M, Mongan N, Diez-Rodriguez M, Nolan CC, Ashankyty I, Ellis IO, Green AR, Rakha EA (2018) Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance. Histopathology 73(6):887\u2013896. https:\/\/doi.org\/10.1111\/his.13695","journal-title":"Histopathology"},{"issue":"3","key":"5757_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10549-016-4072-9","volume":"161","author":"YR Chung","year":"2017","unstructured":"Chung YR, Kim HJ, Jang MH, Park SY (2017) Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status. Breast Cancer Res Treat 161(3):409\u2013420. https:\/\/doi.org\/10.1007\/s10549-016-4072-9","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"5757_CR26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.tranon.2018.12.005","volume":"12","author":"I Catacchio","year":"2019","unstructured":"Catacchio I, Silvestris N, Scarpi E, Schirosi L, Scattone A, Mangia A (2019) Intratumoral, rather than stromal, CD8+T cells could be a potential negative prognostic marker in invasive breast cancer patients. Transl Oncol 12(3):585\u2013595. https:\/\/doi.org\/10.1016\/j.tranon.2018.12.005","journal-title":"Transl Oncol"},{"issue":"1","key":"5757_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-010-0987-8","volume":"127","author":"SM Mahmoud","year":"2011","unstructured":"Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Lee AH, Ellis IO, Green AR (2011) An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 127(1):99\u2013108. https:\/\/doi.org\/10.1007\/s10549-010-0987-8","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"5757_CR28","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.ejso.2017.01.011","volume":"43","author":"F Qian","year":"2017","unstructured":"Qian F, Qingping Y, Linquan W, Xiaojin H, Rongshou W, Shanshan R, Wenjun L, Yong H, Enliang L (2017) High tumor-infiltrating FoxP3(+) T cells predict poor survival in estrogen receptor-positive breast cancer: a meta-analysis. Eur J Surg Oncol 43(7):1258\u20131264. https:\/\/doi.org\/10.1016\/j.ejso.2017.01.011","journal-title":"Eur J Surg Oncol"},{"key":"5757_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/apm.13022","author":"B Cai","year":"2019","unstructured":"Cai B, Ma P, Ding P, Sun DW, Bu Q, Zhang J (2019) Composition and plasticity of triple-negative breast carcinoma-infiltrating regulatory T cells. APMIS. https:\/\/doi.org\/10.1111\/apm.13022","journal-title":"APMIS"},{"issue":"3","key":"5757_CR30","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1007\/s13277-015-4224-2","volume":"37","author":"M Grimm","year":"2016","unstructured":"Grimm M, Feyen O, Hofmann H, Teriete P, Biegner T, Munz A, Reinert S (2016) Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue. Tumour Biol 37(3):3807\u20133816. https:\/\/doi.org\/10.1007\/s13277-015-4224-2","journal-title":"Tumour Biol"},{"issue":"5","key":"5757_CR31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00262-013-1395-9","volume":"62","author":"VL Green","year":"2013","unstructured":"Green VL, Michno A, Stafford ND, Greenman J (2013) Increased prevalence of tumour infiltrating immune cells in oropharyngeal tumours in comparison to other subsites: relationship to peripheral immunity. Cancer Immunol Immunother CII 62(5):863\u2013873. https:\/\/doi.org\/10.1007\/s00262-013-1395-9","journal-title":"Cancer Immunol Immunother CII"},{"issue":"5","key":"5757_CR32","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.urolonc.2010.08.009","volume":"30","author":"CT Lin","year":"2012","unstructured":"Lin CT, Tung CL, Tsai YS, Shen CH, Jou YC, Yu MT, Wu SF (2012) Prognostic relevance of preoperative circulating CD8-positive lymphocytes in the urinary bladder recurrence of urothelial carcinoma. Urol Oncol 30(5):680\u2013687. https:\/\/doi.org\/10.1016\/j.urolonc.2010.08.009","journal-title":"Urol Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05757-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05757-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05757-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:16:21Z","timestamp":1624407381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05757-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["5757"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05757-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]},"assertion":[{"value":"31 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}